Taysha Gene Therapies, Inc. Common Stock (TSHA)
Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodegenerative diseases and monogenic rare disorders. Founded with a mission to deliver transformative treatments, Taysha leverages its proprietary platform to develop innovative viral vector-based therapies aimed at addressing the underlying causes of these conditions. The company collaborates with academic institutions and industry partners to advance its pipeline of potential treatments.
Company News
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
16 analysts have shared their evaluations of Taysha Gene Therapies (NASDAQ:TSHA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Som...
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
These innovation-oriented companies could take flight this year.
Insiders are buying these penny stocks in November. Are they on your watch list? The post Which Penny Stocks Are Best? 3 That Insiders Like In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
